Key facts
- Tamarind Bio’s last known valuation is $57.5M (Feb 2026).
- It has raised $14.1M across 1 recorded rounds; the latest was Early Stage VC ($13.6M) in May 2025.
- Notable investors include Y Combinator, Transpose Platform Management, 468 Capital, Phosphor Capital, Dimension (United States) — 7 tracked in total.
- Tamarind Bio has filed 1 Form D with the SEC, most recently May 2025 ($13.6M sold to 24 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Tamarind Bio
Funding rounds
1 roundsAbout Tamarind Bio
Developer of a no-code computational instrument designed to allow researchers to use bioinformatics tools at scale using a simple interface. The company offers tools focusing on structural biology, including protein structure prediction, protein design, and molecular docking, enabling scientists to use specialized tools by selecting inputs instead of writing code or setting up a high-performance computing environment.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2023
- Employees
- 7
- Website
- tamarind.bio/
- Ownership
- Privately Held (backing)
Tamarind Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tamarind Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tamarind Bio in its N-PORT filings yet. We sweep new filings monthly.